Parkinson’s Disease – Market Access and Reimbursement Insights Report – 2025

Parkinson’s Disease Market Access and Reimbursement Insights

Thelansis’s “Parkinson’s Disease Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities.

Parkinson’s Disease Overview

Parkinson’s Disease (PD) is recognized as a complex, chronic, and progressive multisystem neurodegenerative disorder, not solely a motor system disorder, resulting from the progressive loss of dopamine-producing neurons in the substantia nigra pars compacta and the accumulation of misfolded alpha-synuclein protein into Lewy bodies, which also spread to other brain regions and the peripheral nervous system years before diagnosis. The classic motor features required for clinical diagnosis according to the Movement Disorder Society (MDS) criteria include bradykinesia (slowness of movement) along with at least one of the following: resting tremor (often “pill-rolling”), or rigidity (stiffness), with postural instability typically manifesting in later stages. Crucially, the up-to-date understanding emphasizes the significant and often disabling non-motor symptoms that can predate motor onset by years—such as olfactory dysfunction (loss of smell), REM sleep behavior disorder (acting out dreams), constipation, and mood disorders like depression and anxiety—all reflecting disturbances in non-dopaminergic systems that are now integral to the contemporary diagnostic and treatment paradigm.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* and interviews with payers (e.g., pharmacy directors / medical directors from managed care organizations with Medicare and/or Commercial plans in the United States). If required, primary market research with physicians is also done to understand the impact of reimbursement environment on treatment decisions for current and emerging brands.

*Survey and interview discussion guide are customized based on client requirements

Deliverables format:

• PowerPoint presentation

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Key business questions answered:

• Market access and reimbursement for current therapies
• Coverage on plans
• Market access restrictions
• Rebates and contracting
• Factors influencing formulary access
• HEOR requirements and influence, etc.
• Expected market access and reimbursement for key emerging therapies
• Level of awareness
• Anticipated coverage on plans
• Factors that would improve market access
• Pricing, etc.
• Impact on brand use
• Key factors driving and limiting brand use
• Best and worst performers on market access, etc.
• Evolving environment
• Payer expectations from emerging therapies
• New policies and their expected impact, etc.
• Advise to drug manufacturers and developers

Read more: Parkinson’s Disease – Market Access and Reimbursement Insights Report – 2025